Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Helen Ross, MD
Rush University
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California San Diego Moores Cancer Center
La Jolla, California, United States
- Kaiser Permanente Oakland Medical Center
Oakland, California, United States
- Kaiser Permanente Roseville Medical Center
Roseville, California, United States
- Kaiser Permanente San Francisco Medical Center
San Francisco, California, United States
- Kaiser Permanente Santa Clara Medical Center
Santa Clara, California, United States
- Kaiser Permanente Vallejo Medical Center
Vallejo, California, United States
- Rush University Medical Center
Chicago, Illinois, United States
- Missouri Baptist Medical Center
St Louis, Missouri, United States
- Washington University Siteman Cancer Center
St Louis, Missouri, United States
- University of Nebraska Medical Center
Omaha, Nebraska, United States
- New Hampshire Oncology - Hematology, Pa
Manchester, New Hampshire, United States
- Hematology Oncology Associates of Central New York, P.C.
East Syracuse, New York, United States
- Suny Upstate Medical University
Syracuse, New York, United States
- Ohio State University
Columbus, Ohio, United States
- University of Wisconsin
Madison, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 7 Dec 2023
- Primary completion
- 30 Nov 2026
- Completion
- 30 Nov 2026
- Last update posted
- 9 Jun 2026
- Registered enrollment
- 178
- Registry id
- NCT05798663
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.